Does Fosamax Cause Osteonecrosis of the Jaw?

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Targeted Exposure Inquiry

The legacy domain of general health and science information has long served as a foundational resource for public understanding of medical conditions and treatments. Within this broad context, the dissemination of knowledge about pharmaceutical interventions and their potential side effects has been a key responsibility. As the digital landscape evolves, there is a natural progression from this general health heritage toward more specialized, exposure-focused inquiries. This shift is particularly relevant when considering the transition from broad patient education to the specific concerns of individuals who have been prescribed or are considering medications such as bisphosphonates. The focus now narrows to a critical question that bridges general health awareness with a specific occupational or clinical exposure scenario: the potential link between Fosamax (alendronate) use and the development of osteonecrosis of the jaw.

Bridging General Awareness to Specific Risk Assessment

This pivot moves the discussion from a general informational context to a targeted examination of risk associated with a particular drug exposure, setting the stage for a detailed exploration of causation without delving into mechanistic claims. Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its primary mechanism involves inhibiting bone resorption by osteoclasts, thereby increasing bone mass and reducing fracture risk. However, a known adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the maxillofacial region.

Clinical Presentation and Diagnosis of ONJ

Clinical presentation and diagnosis of ONJ typically involve exposed bone in the jaw that persists for more than eight weeks, often accompanied by pain, swelling, infection, or delayed healing after dental procedures. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Diagnosis is primarily clinical, supported by imaging such as panoramic radiographs or CT scans, which may reveal bone necrosis, sequestra, or periosteal reaction. The multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Mechanistic Pathways and Risk Factors

The mechanistic pathways linking Fosamax to ONJ are not fully elucidated but are thought to involve several factors. Bisphosphonates accumulate in bone, particularly in areas of high turnover such as the jaw, and suppress osteoclast activity. This suppression can impair bone remodeling and microdamage repair, leading to avascular necrosis. Additionally, bisphosphonates may inhibit angiogenesis, reduce blood supply to the jawbone, and alter immune responses, increasing susceptibility to infection. The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Known risk factors include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Adequacy of Warnings and Label Information

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under "Warnings and Precautions." It states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also notes that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label does not provide specific guidance on the optimal duration of use, noting that the optimal duration has not been determined and that for low-risk patients, discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while warnings exist, they may not fully address the cumulative risk over long-term exposure.

Causation Considerations and Temporal Association

Causation-related considerations for affected patients involve establishing a temporal relationship between Fosamax use and the development of ONJ. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, and a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a recognized adverse effect, its incidence in clinical trials was low and not significantly different from placebo, complicating direct causation. However, post-marketing reports and case series have established a link, particularly in patients with additional risk factors.

Timeline, Management, and Prognosis

The timeline between exposure and documented harm can vary widely. ONJ may develop after months to years of bisphosphonate use, with risk increasing with longer exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Acute onset within days is possible but less common. The condition often presents after a dental procedure, which may act as a precipitating event. For patients who develop ONJ, management includes discontinuation of the bisphosphonate, oral antimicrobial rinses, antibiotics, and in severe cases, surgical debridement. The prognosis varies, with some patients experiencing resolution after stopping the drug, while others may have persistent or recurrent disease. In summary, Fosamax is associated with an increased risk of osteonecrosis of the jaw, particularly in patients with additional risk factors such as dental procedures, cancer, or concomitant medications. The prescribing information includes warnings, but the risk may be underappreciated in long-term users. Causation is supported by temporal association, dechallenge-rechallenge responses, and biological plausibility, though the absolute risk is low. Patients should be counseled on maintaining good oral hygiene and avoiding invasive dental procedures during treatment when possible.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the primary mechanism by which Fosamax increases the risk of osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that inhibits bone resorption by osteoclasts. It accumulates in bone, particularly in high-turnover areas like the jaw, suppressing osteoclast activity and impairing bone remodeling and microdamage repair. This can lead to avascular necrosis. Additionally, it may inhibit angiogenesis and alter immune responses, increasing infection susceptibility (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the known risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (periodontal disease, anemia, coagulopathy, infection, ill-fitting dentures). Duration of bisphosphonate exposure also increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How is osteonecrosis of the jaw diagnosed?

Diagnosis is primarily clinical, based on exposed bone in the jaw persisting for more than eight weeks, often with pain, swelling, or infection. Imaging such as panoramic radiographs or CT scans may reveal bone necrosis, sequestra, or periosteal reaction (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.